COMPANY MANAGEMENT

Chief Scientific Officer
Rodney Lappe, PhD, joined CovX in January 2004, bringing 23 years of drug discovery experience in the pharmaceutical industry. He has been responsible for the advancement of large portfolios of drug discovery projects and has promoted multiple therapeutic candidates through pre-clinical and clinical development. He brings a strong understanding of pharmacology, a clear strategic scientific vision and extensive experience in international drug discovery collaborations. Most recently, Dr. Lappe served as vice president for cardiovascular and metabolic diseases at Pharmacia where he contributed to the registration of Inspra^®, a novel aldosterone receptor antagonist. He was also the site leader for Pharmacia in St. Louis. Prior to joining Pharmacia, he held positions of increasing responsibility with Wyeth Laboratories, Rorer Central Researh, CIBA Geigy Pharmaceuticals and Searle Pharmaceuticals. Dr. Lappe received his PhD in Pharmacology from Indiana University and his BA from Blackburn College.

Vice President, Chemistry
Curt Bradshaw, PhD, has been responsible for discovery and development chemistry efforts at CovX since the founding of the company in 2002. The chemistry team identifies novel applications of CovX technology, advances research and development programs and drives Good Manufacturing Practice (GMP) small-molecule and peptide programs. Previously, he has held positions of increasing responsibility supporting pre-clinical, clinical and commercial therapeutic programs of small molecules and biologics at Abbott Laboratories and Ligand Pharmaceuticals. Dr. Bradshaw received his PhD in organic chemistry from Texas A&M University and conducted research at The Scripps Research Institute in La Jolla, California.

Vice President, Preclinical Development
Stanley Roberts, PhD, joined CovX in January, 2006 with primary responsibilities for the preclinical development programs. He has over 24 years of preclinical safety experience in the pharmaceutical industry (Sandoz and Abbott) in both scientific and management roles in toxicology and drug metabolism. Dr. Roberts has led improvements in the drug discovery-development interface by successfully integrating the research from pharmacology, pharmacokinetics, drug metabolism, mechanistic toxicology and regulatory toxicology/pathology. He is a Diplomate of the American Board of Toxicology and is a highly sought lecturer in the areas of toxicology, drug metabolism and drug development. He received his BS in Animal Science and his PhD in Pharmacology/Toxicology from Purdue University.

Vice President, Clinical and Regulatory Affairs
Steven Schoenfeld, MD, joined CovX in December, 2005 bringing more than 16 years of clinical drug development experience from both large pharmaceutical and biotech companies including Amylin Pharmceuticals, CIBA-Geigy Pharmaceuticals, Isis Pharmaceuticals, Procter and Gamble, Pharmacia, and Pfizer. He was global project leader for multiple compounds while working at Pharmacia and subsequently Pfizer’s European drug development headquarters in the UK. During his career, Dr. Schoenfeld has been responsible for the filing of multiple NDA/SNDAs, INDs and CTAs and has had frequent interactions with the FDA, EMEA/CHMP and PMDA. Dr. Schoenfeld has developed drugs in several therapy areas including metabolic bone diseases and osteoporosis, diabetes, inflammatory bowel syndrome, growth disorders and oncology. Most recently, Dr. Schoenfeld served as senior director, oncology clinical development at Pfizer. Dr. Schoenfeld received his MD from New York Medical College and his BS in biomedical sciences from the Sophie Davis School of Biomedical Education of the City College of New York.

Vice President, Human Resources
Robin Vedova joined CovX in January, 2006 bringing over 25 years Human Resources and Administration experience.  Prior to joining CovX, she was vice president of administration for Gen-Probe.  In addition, Ms. Vedova has held various positions with Becton Dickinson and Bausch & Lomb.  She graduated from the University of San Diego with a Master’s Degree in Executive Leadership and has her SPHR certification.  Ms. Vedova is an active member of the Corporate Director’s Forum and a board member of the Healthcare Businesswomen’s Association for Southern California.

Vice President, Development Operations
Gary H. Ward, PhD, joined CovX in July, 2003 and is responsible for pharmaceutical product development of CovX programs. Over the past 15 years, he has held increasing levels of responsibility and led formulation and process development efforts at 3M Company, Dura Pharmaceuticals, Élan Corporation, and Chugai Biopharmaceuticals. Dr. Ward has produced the chemistry, manufacturing and controls sections of numerous IND and NDA submissions. He received his PhD in pharmaceutical science from the University of Arizona and has authored more than 60 papers and abstracts and is listed as the inventor on six patents in the areas of pharmaceutical pre-formulation, formulation and process development.

Vice President, Biology
Gary Woodnutt, PhD, joined CovX in March, 2006 as head of biology and brings more than 25 years of experience in the pharmaceutical industry. Before joining CovX, Dr. Woodnutt was head of pharmaceutical research and development at Diversa where he oversaw all efforts related to the optimization of therapeutic proteins and small molecule discovery. Prior to Diversa, he was at GlaxoSmithKline where he was vice president of biology, microbial, musculoskeletal and proliferative disease CEDD and responsible for discovery and non-clinical development and market support activities in the anti-infective and host defense areas. During his time with GlaxoSmithKline, Dr. Woodnutt contributed to multiple IND and NDA filings for anti-infective drugs. He is on the editorial board of Antimicrobial Agents and Chemotherapy and is a section editor for Drug Discovery Today: Therapeutic Strategies and Current Opinion in Biotechnology. He received his Bachelors degree in Biochemistry and Physiology from Leeds University, UK and his PhD from Reading University, UK.